NeurosciencePharmaRare & Genetic DiseasesUnited States Biogen Posts $2.5B Q1 Revenue as LEQEMBI Persistence Data and SPINRAZA Approval Reframe Post-Aduhelm Narrative Biogen reports $2.5B Q1 revenue, +2% YoY, with non-GAAP EPS of $3.57, up 18%. LEQEMBI’s 78% 18-month persistence rate and a new high-dose SPINRAZA FDA approval signal commercial and pipeline … By Fernando PafumiMay 24, 20266 Comments
IHME: Global Health Funding Falls Another 5% in 2026 After Hitting Lowest Level Since 2012 Nov 16, 2026
You must be logged in to post a comment.